# Chromosome 3p Deletion Leads to Extensive Genomic Alterations in Diverse Cancers and Confers Synthetic Lethality in Uveal Melanoma

**Authors:** Mitchell C. Cutler, Porter B. Howland, Miroslav Hejna, Jun S. Song

PMC · DOI: 10.3390/cancers18040688 · 2026-02-19

## TL;DR

Deleting part of chromosome 3p causes genomic instability in many cancers and creates a treatment target in uveal melanoma.

## Contribution

The study reveals how chr3p deletion leads to isochromosomes and identifies MITF as a key driver in uveal melanoma with therapeutic implications.

## Key findings

- SETD2 deletion or mutation on chr3p promotes isochromosome formation and genomic instability in diverse cancers.
- MITF hemizygous deletion in uveal melanoma drives compensatory evolution and influences patient survival.
- Combinatorial targeting of MITF and synthetic lethal genes may improve outcomes for uveal melanoma patients with chr3p deletion and 8q+ amplification.

## Abstract

Isochromosomes are chromosomal aberrations consisting of two identical mirror-imaged arms and simultaneous deletion of the complementary arms. We show that SETD2 deleterious mutations or hemizygous deletion of chr3p containing the gene leads to isochromosomes in cancer patients. Dicentric isochromosomes, known to form a chromatin bridge between dividing cells, are prone to massive fragmentation, which can be modeled computationally. In uveal melanoma (UVM), chr3 deletion also includes MITF, but we show that MITF is a master regulator of key driver genes of UVM. We demonstrate how this accidental hemizygous deletion of MITF in UVM imposes a strong selection pressure on subsequent compensatory genome evolution, explains differences in patient survival, and provides therapeutic opportunities.

Background: Chromosome 3p (chr3p) is frequently deleted in multiple cancers, indicating the presence of shared tumor suppressors. In aggressive uveal melanomas (UVM), this deletion often co-occurs with chr8q amplification (8q+), suggesting strong selection pressure during UVM evolution. Methods: To understand the pattern of genomic alterations mediated by chr3p deletion, we have developed an algorithm for detecting isochromosomes in 10,632 TCGA cancer patients. We further perform integrative genomics analysis to investigate how chr3p deletion could affect subsequent cancer genome evolution and synthetic lethality in UVM. Results: Analysis of genomic alterations in 33 different cancer types implicates the deletion or deleterious mutations of SET-domain-containing 2 (SETD2) at chr3p21 in significantly facilitating the formation of isochromosomes, thereby promoting genomic instability conducive to rapid cancer genome evolution. Fracturing of dicentric isochromosomes during cell division is pervasive and follows the dynamic fragmentation pattern of solids under impulse. In the most aggressive UVM subtype, chr3 deletion includes MITF, a master regulator of melanocyte survival and differentiation, and co-occurs with 8q+. We demonstrate that MITF is a master transcriptional regulator of GNAQ/GNA11 and associated synthetic-lethal genes in UVM. MITF maintains MAPK and calcium homeostasis in UVM, and its hemizygous deletion is thus accidental, likely creating an early crisis during oncogenesis. We further show that MITF, MYC, and GNAQ/GNA11 form coupled regulatory feedback loops in the melanocyte lineage, and MITF deletion in UVM creates acute dependency on MYC-mediated rescue via 8q+. The discovered feedback loops predict both overall and relapse-free patient survival within the most aggressive UVM subtype, explain sensitivity to therapeutic gene perturbations, and inform effective combinatorial therapies. Conclusions: SETD2 deletion potentiates isochromosome formation across diverse cancers. Combinatorial targeting of MITF together with a previously identified synthetic lethal gene may benefit UVM patients harboring both chr3 deletion and 8q+.

## Linked entities

- **Genes:** SETD2 (SET domain containing 2, histone lysine methyltransferase) [NCBI Gene 29072], MITF (melanocyte inducing transcription factor) [NCBI Gene 4286], GNAQ (G protein subunit alpha q) [NCBI Gene 2776], GNA11 (G protein subunit alpha 11) [NCBI Gene 2767], MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609]
- **Diseases:** uveal melanoma (MONDO:0006486), cancer (MONDO:0004992)

## Full-text entities

- **Genes:** CREB1 (cAMP responsive element binding protein 1) [NCBI Gene 1385] {aka CREB, CREB-1}, MTMR9 (myotubularin related protein 9) [NCBI Gene 66036] {aka C8orf9, LIP-STYX, MTMR8}, TUBA1B (tubulin alpha 1b) [NCBI Gene 10376] {aka K-ALPHA-1}, ADCY6 (adenylate cyclase 6) [NCBI Gene 112] {aka AC6, LCCS8}, CDS2 (CDP-diacylglycerol synthase 2) [NCBI Gene 8760], GNA11 (G protein subunit alpha 11) [NCBI Gene 2767] {aka FBH, FBH2, FHH2, GNA-11, HG1K, HHC2}, GNAQ (G protein subunit alpha q) [NCBI Gene 2776] {aka CMAL, G-ALPHA-q, GAQ, SWS}, PSIP1 (PC4 and SRSF1 interacting protein 1) [NCBI Gene 11168] {aka DFS70, LEDGF, PAIP, PSIP2, p52, p75}, STIM1 (stromal interaction molecule 1) [NCBI Gene 6786] {aka D11S4896E, GOK, IMD10, STRMK, TAM, TAM1}, STAMBP (STAM binding protein) [NCBI Gene 10617] {aka AMSH, MICCAP}, HUWE1 (HECT, UBA and WWE domain containing E3 ubiquitin protein ligase 1) [NCBI Gene 10075] {aka ARF-BP1, HECTH9, HSPC272, Ib772, LASU1, MRXST}, MLANA (melan-A) [NCBI Gene 2315] {aka MART-1, MART1}, BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672] {aka BRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4}, ZBTB17 (zinc finger and BTB domain containing 17) [NCBI Gene 7709] {aka MIZ-1, ZNF151, ZNF60, pHZ-67}, SETD2 (SET domain containing 2, histone lysine methyltransferase) [NCBI Gene 29072] {aka HBP231, HIF-1, HIP-1, HSPC069, HYPB, KMT3A}, CCND1 (cyclin D1) [NCBI Gene 595] {aka BCL1, D11S287E, PRAD1, U21B31}, BAP1 (BRCA1 associated deubiquitinase 1) [NCBI Gene 8314] {aka HUCEP-13, KURIS, TPDS1, UBM2, UCHL2, UVM2}, PHF19 (PHD finger protein 19) [NCBI Gene 26147] {aka MTF2L1, PCL3, TDRD19B}, LGR5 (leucine rich repeat containing G protein-coupled receptor 5) [NCBI Gene 8549] {aka FEX, GPR49, GPR67, GRP49, HG38}, RAD51 (RAD51 recombinase) [NCBI Gene 5888] {aka BRCC5, FANCR, HRAD51, HsRad51, HsT16930, MRMV2}, GAB2 (GRB2 associated binding protein 2) [NCBI Gene 9846], GNAS (GNAS complex locus) [NCBI Gene 2778] {aka AHO, AIMAH1, C20orf45, GNAS1, GPSA, GSA}, MITF (melanocyte inducing transcription factor) [NCBI Gene 4286] {aka CMM8, COMMAD, MI, MITF-A, WS2, WS2A}, RASGRP3 (RAS guanyl releasing protein 3) [NCBI Gene 25780] {aka GRP3}, PVT1 (Pvt1 oncogene) [NCBI Gene 5820] {aka LINC00079, MIR1204HG, NCRNA00079, TP53LC09, onco-lncRNA-100}, Rasgrp3 (RAS, guanyl releasing protein 3) [NCBI Gene 240168] {aka Gm327}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, Mitf (melanogenesis associated transcription factor) [NCBI Gene 17342] {aka BCC2, Bhlhe32, Gsfbcc2, Vitiligo, Wh, bw}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, MC1R (melanocortin 1 receptor) [NCBI Gene 4157] {aka CMM5, MSH-R, SHEP2}, INPP5A (inositol polyphosphate-5-phosphatase A) [NCBI Gene 3632] {aka 5PTASE}
- **Diseases:** toxicity (MESH:D064420), death (MESH:D003643), metastasis (MESH:D009362), Papillary Renal-Cell Carcinoma (MESH:D002292), aneuploidy (MESH:D000782), CIN (MESH:D043171), SKCM (MESH:C562393), UVM (MESH:C536494), breast cancer (MESH:D001943), M3 (MESH:D015473), pigmentation (MESH:D010859), Cancers (MESH:D009369), Multiple (MESH:D009104), Waardenburg Syndrome (MESH:D014849), skin cutaneous melanomagenesis (MESH:D012871), PAAD (MESH:D010190), fracture (MESH:D050723), melanoma (MESH:D008545), D3 (MESH:D024182), injury to (MESH:D014947), HNSC (MESH:D000077195), oncogenesis (MESH:D063646), SKCM cancers (MESH:D012878)
- **Chemicals:** L-phenylalanine (MESH:D010649), GSM5750556 (-), calcium (MESH:D002118), DMSO (MESH:D004121), DAG (MESH:D004075), guanine (MESH:D006147), PLX4032 (MESH:D000077484), PIP2 (MESH:D019269), Doxycycline (MESH:D004318), IP3 (MESH:D015544)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** A375, BRAFV600E
- **Cell lines:** D3 — Homo sapiens (Human), Uveal melanoma, Cancer cell line (CVCL_C298), MEL202 — Homo sapiens (Human), Uveal melanoma, Cancer cell line (CVCL_C301), M3 — Homo sapiens (Human), Amelanotic melanoma, Cancer cell line (CVCL_8336), SKCM — Canis lupus familiaris (Dog), Canine mastocytoma, Cancer cell line (CVCL_WH42), Ma-Mel-63a — Homo sapiens (Human), Melanoma, Cancer cell line (CVCL_A198), A375P — Homo sapiens (Human), Amelanotic melanoma, Cancer cell line (CVCL_6233), A375 — Homo sapiens (Human), Amelanotic melanoma, Cancer cell line (CVCL_0132), NZM015 — Homo sapiens (Human), Melanoma, Cancer cell line (CVCL_D821), WM3772F — Homo sapiens (Human), Uveal melanoma, Cancer cell line (CVCL_0B81), SK-MEL-28 — Homo sapiens (Human), Cutaneous melanoma, Cancer cell line (CVCL_0526), GSE115845 — Konosirus punctatus (Dotted gizzard shad), Spontaneously immortalized cell line (CVCL_6F81), UPMM3 — Homo sapiens (Human), Uveal melanoma, Cancer cell line (CVCL_C295), COLO829 — Homo sapiens (Human), Cutaneous melanoma, Cancer cell line (CVCL_1137), MeWo — Homo sapiens (Human), Cutaneous melanoma, Cancer cell line (CVCL_0445), M397 — Homo sapiens (Human), Melanoma, Cancer cell line (CVCL_XK00), MEL270 — Homo sapiens (Human), Uveal melanoma, Cancer cell line (CVCL_C302), NZM012 — Homo sapiens (Human), Melanoma, Cancer cell line (CVCL_D818), A2058 — Homo sapiens (Human), Amelanotic melanoma, Cancer cell line (CVCL_1059), ENCODE — Homo sapiens (Human), Glioblastoma, Cancer cell line (CVCL_B1CX)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12939820/full.md

---
Source: https://tomesphere.com/paper/PMC12939820